Navigation Links
PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Date:3/23/2010

development expenses for 2009 consisted primarily of research and development activities related to the Company's Valortim® and Protexia® development programs as well as to the SparVax, RypVax™ and third generation anthrax vaccine programs. The $1.6 million decrease in research and development expenses was primarily due to a reduction in preclinical development costs for the Protexia® program as the Company progressed in its clinical evaluation phase, and a reduction in development costs for its plague vaccine program, partially offset by increased preclinical development costs associated with the Company's anthrax-related therapeutics and vaccines programs.

General and administrative expenses were $22.4 million and $19.4 million for the years ended December 31, 2009 and 2008, respectively. The increase in general and administrative expenses was primarily due to costs associated with transitioning the Company's development and manufacturing activities for the SparVax and third generation anthrax vaccine programs, along with other general and administrative functions from the UK to the United States, and with preparing and submitting various bids and proposals, along with increased non-cash, stock-based compensation costs during 2009.

For the year ended December 31, 2009, PharmAthene's net loss was

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
2. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
3. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
6. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
9. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
(Date:8/21/2014)... August 21, 2014 SoundConnect ... been recognized as one of the nation’s Fastest ... magazine for the 2nd consecutive year. Inc. magazine ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2
... Management and Patient,Safety Institute (RM&PSI) today announced its ... RM&PSI ( http://www.rmpsi.com ), a subsidiary of FinCor,Holdings ... in,clinical risk management and patient safety programs and ... The spring 2009 calendar also ...
... new white papers detailing sterility testing essentials are ... www.microtestlabs.com ). The white papers, one which ... which is specialized for pharmaceutical manufacturers, presents the ... and reviews different testing methodologies.For medical device manufacturers, ...
... NEOG ) has received approval from the ... its quick and easy BetaStar(R)US test,for dairy antibiotics in ... United States to use Neogen,s new test to comply ... for dairy antibiotics. , Neogen,s ...
Cached Biology Technology:The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 2The Risk Management and Patient Safety Institute Announces Winter and Spring 2009 Audio Program Lineup, Annual Conference Dates 3Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Neogen's BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS 2
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan Service ... agreed to a partnership with Gabriel Health Institute, ... fastest growing Certified Nursing Assistant preparatory schools. ...  an exclusive member of Binary,s LiveScan service provider,s ... will improve its service capabilities by widening ...
(Date:8/21/2014)... window? It consists of radiations in the 3.3 to ... water in biological tissues. New theoretical findings show that ... water window. These could be the basis of an ... biological samples or to be used in high-precision spectroscopy. ... needed to efficiently generate the harmonic radiationswhich are multiples ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Water window imaging opportunity 2
... to each person or set of identical twins. That ... crime detection to international travel. But what happens when ... patterns of ridges? It,s not the premise ... known as adermatoglyphia. It,s also known as "Immigration Delay ...
... on the detrimental impact of some common medicines on elderly people ... a few of these medicines does not appear to cause further ... In a paper published today by the journal ... East Anglia (UEA) and colleagues from a number of other universities ...
... - The first fluorescence-guided surgery on an ovarian cancer patient ... agent created by a Purdue University researcher. The surgery ... phase of a clinical trial to evaluate a new technology ... ovarian cancer patients. The method illuminates cancer cells to help ...
Cached Biology News:Shake hands with the invisible man 2Reassurance for dementia sufferers on impact of common drugs 2Purdue technology used in first fluorescence-guided ovarian cancer surgery 2Purdue technology used in first fluorescence-guided ovarian cancer surgery 3Purdue technology used in first fluorescence-guided ovarian cancer surgery 4
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... Zeba Desalt Spin Columns contain a proprietary ... offers exceptional desalting and protein-recovery characteristics compared ... as low as 25 g/ml of protein ... and > 95% retention of salts and ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Biology Products: